Multifocal soft tissue sarcoma: Limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan

Journal of Surgical Oncology

Volumn 70, Issue 3, 1999, Pages 185-189

  Lev Chelouche, Dina ^a   Abu Abeid, Subhi ^a   Kollander, Yehuda ^a   Meller, Isaac ^a   Isakov, Josephine ^a   Merimsky, Ofer ^a   Klausner, Joseph M ^a   Gutman, Mordechai ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Isolated limb perfusion; Melphalan; Multifocal soft tissue sarcoma; Tumor necrosis factor

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LIMB AMPUTATION; LIMB PERFUSION; LIMB SALVAGE; MALE; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

EID: 0033013236     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1096-9098(199903)70:3<185::aid-jso8>3.0.co;2-%23     Document Type: Article

References (22)

1. Rosenberg SA, Suit HD, Barker LH: Sarcomas of soft tissue. In Devita VT, Hellman S, Rosenberg SA (eds): "Cancer Principles and Practice of Oncology." Philadelphia: J.B. Lippincott, 1993: 1436-1488.
2. Krementz ET, Carter RD, Sutherland CM, et al.: Chemotherapy of sarcomas of the limbs in regional perfusion. Ann Surg 1977;185: 555-563.
3. McBride CM: Sarcomas of the limbs: Results of adjuvant chemotherapy using isolation perfusion. Arch Surg 1974;109:304-308.
4. Hoekstra HS, Schraffordt-Koops H, Molenaar WM, et al.: Results of isolated regional perfusion in the treatment of soft tissue tumors of the extremities. Cancer 1987;60:1703-1707.
5. Gutman M, Inbar M, Lev-Shlush D, et al.: High dose tumor necrosis factor-α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997;79:1129-1137.
6. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al.: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: The cumulative multicenter European experience. Ann Surg 1996;224:756-765.
7. Tracey KJ, Beutler B, Lowry SF, et al.: Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-473.
8. Wieberdink J, Benckhuijsen C, Braat RP, et al.: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-910.
9. Ruka W, Emrich LJ, Driscoll DL, et al.: Clinical factors and treatment parameters affecting prognosis in adult high grade soft tissue sarcomas: A retrospective review of 267 cases. Eur J Surg Oncol 1989;15:411-423.
10. Lawrence W, Donegan WI, Natrajan N, et al.: Adult soft tissue sarcomas: A pattern of care survey of the American College of Surgeons. Ann Surg 1987;205:349-359.
11. Klaase JM, Kroon BBR, Benckhuysen C, et al.: Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989;64:616-621.
12. Rossi CR, Vecchiato A, Foletto M, et al.: Phase II study on neo-adjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate high grade limb sarcomas. Cancer 1994;73:2140-2146.
13. Haranaka K, Satomi N, Sukari A: Antitumor activity of murine tumor necrosis factor against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 1984; 34:263-267.
14. Sugarman BJ, Aggarwal BB, Hass PF, et al.: Recombinant tumor necrosis factor-α: Effects of proliferation of normal and transformed cells in vitro. Science 1985;230:943-945.
15. Quinn TD, Polk HCJ, Edwards MJ: Hyperthermic isolated limb perfusion increases circulating levels of inflammatory cytokines. Cancer Immunol Immunother 1995;40:272-275.
16. Beutler B, Cerami A: Tumor necrosis, cachexis shock and inflammation: A common mediator. Annu Rev Biochem 1988;57:505-518.
17. Watanabe N, Niitsu Y, Umeno H, et al.: Toxic effect of TNF on tumor vasculature in mice. Cancer Res 1988;49:179-183.
18. Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-745.
19. Bevilacqua MP, Pober JS, Majeau GR, et al.: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium. Characterization and comparison with actions of interleukin-1. Proc Natl Acad Sei USA 1986;83:4533-4537.
20. Cheresh DA: Integrin αVβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. 38th Annual Conference on Advances in the Biology and Clinical Management of Melanoma, Houston, TX, 21-24 February 1995.
21. Regeness A, Muller M, Curschellas E, et al.: Antitumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int J Cancer 1987;39:266-273.
22. Folli S, Pelegrini A, Chalandon Y, et al.: Tumor necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993; 53:829-836.